Author

Anil Baskan

Medical University of Vienna

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

Andreas TiefenbacheriD· 2 shared Gerda EggeriD· 2 shared Jessica KallaiD· 2 shared Kristina DraganićiD· 2 shared Theresia MairiD· 2 shared Carlos Uziel Pérez MallaiD· 1 shared Emine Atas· 1 shared Gabriel WasingeriD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Andreas TiefenbacherORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss

Jessica Kalla, Thomas Dillinger, Zlata Pavlovicova, Reema Jacob, Emine Atas, Katarina Mišura, Anil Baskan, Kristina Draganić, Andreas Tiefenbacher, Tanja Limberger, Theresia Mair, Gabriel Wasinger, Ludovica Villanti, Stefan Kubicek, Lukas Kenner, Gerda Egger

This study establishes a murine tumoroid biobank to identify oncogenic pathways and drug vulnerabilities in prostate cancer, finding that PTEN loss drives cancer pathways and that specific compounds inhibit tumor growth.

Cell Reports Methods · Mar 30, 2026Peer-reviewedCancer Biology

Aggressive KRAS mutations direct TGF-β response towards partial EMT in patient-derived colorectal cancer tumoroids

Theresia Mair, Philip König, Milena Mijović, Jessica Kalla, Anil Baskan, Loan Tran, Kristina Draganić, Pedro Morata Saldaña, Carlos Uziel Pérez Malla, Janette Pfneissl, Andreas Tiefenbacher, Julijan Kabiljo, Velina S. Atanasova, Lisa Wozelka‐Oltjan, Leonhard Müllauer, , Gerda Egger

This study investigates how TGF-β affects colorectal cancer tumoroids, finding that aggressive KRAS mutations lead to partial EMT and increased invasiveness.

Molecular Oncology · Mar 11, 2025Peer-reviewedCancer Biology